Pfizer Cash and Equivalents Turnover Trend from 2010 to 2022

PFE
 Stock
  

USD 49.75  0.36  0.72%   

Pfizer Cash and Equivalents Turnover is increasing over the years with slightly volatile fluctuation. Ongoing Cash and Equivalents Turnover is projected to grow to 47.05 this year. During the period from 2010 to 2022 Pfizer Cash and Equivalents Turnover anual values regression line had geometric mean of 23.70 and mean square error of  133.34. Pfizer Cost of Revenue is projected to decrease significantly based on the last few years of reporting. The past year's Cost of Revenue was at 9.2 Billion. The current year Gross Profit is expected to grow to about 37.7 B, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to about 18.5 B.
  
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer main balance sheet or income statement drivers, such as Direct Expenses of 33.3 B, Consolidated Income of 17 B or Cost of Revenue of 9.4 B, as well as many exotic indicators such as Interest Coverage of 15.54, Long Term Debt to Equity of 0.45 or Calculated Tax Rate of 9.19. Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules. It can also supplement Pfizer's financial leverage analysis and stock options assessment as well as various Pfizer Technical models . Please check the analysis of Pfizer Correlation against competitors.

Pfizer Cash and Equivalents Turnover Breakdown

Showing smoothed Cash and Equivalents Turnover of Pfizer Inc with missing and latest data points interpolated. Pfizer's Cash and Equivalents Turnover historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Pfizer's overall financial position and show how it may be relating to other accounts over time.
Cash and Equivalents Turnover10 Years Trend
Increasing
Slightly volatile
   Cash and Equivalents Turnover   
Share
       Timeline  

Pfizer Cash and Equivalents Turnover Regression Statistics

Arithmetic Mean 27.51
Geometric Mean 23.70
Coefficient Of Variation 50.52
Mean Deviation 11.58
Median 26.69
Standard Deviation 13.90
Sample Variance 193.14
Range 38.85
R-Value 0.61
Mean Square Error 133.34
R-Squared 0.37
Significance 0.028164
Slope 2.16
Total Sum of Squares 2,318

Pfizer Cash and Equivalents Turnover History

2012 8.45
2013 8.21
2014 17.95
2015 13.99
2016 16.9
2017 26.69
2018 43.25
2019 42.35
2020 27.06
2021 43.61
2022 47.05

About Pfizer Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Pfizer income statement, its balance sheet, and the statement of cash flows. Pfizer investors use historical funamental indicators, such as Pfizer's Cash and Equivalents Turnover, to determine how well the company is positioned to perform in the future. Although Pfizer investors may use each financial statement separately, they are all related. The changes in Pfizer's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Pfizer's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Pfizer Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Pfizer. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Cash and Equivalents Turnover 43.61  47.05 
Free Cash FlowB10.7 B
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and womens health under the Premarin family and Eliquis brands biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the ComirnatyBNT162b2, Nimenrix, FSMEIMMUN-TicoVac, Trumenba, and the Prevnar family brands biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, EucrisaStaquis, and Cibinqo brands and amyloidosis, hemophilia, and endocrine diseases under the VyndaqelVyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company Astellas Pharma US, Inc. Myovant Sciences Ltd. Akcea Therapeutics, Inc Merck KGaA Valneva SE BioNTech SE and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Pfizer without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now

   

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Currently Active Assets on Macroaxis

Please check the analysis of Pfizer Correlation against competitors. Note that the Pfizer Inc information on this page should be used as a complementary analysis to other Pfizer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Pfizer Stock analysis

When running Pfizer Inc price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Is Pfizer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pfizer. If investors know Pfizer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pfizer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
0.77
Market Capitalization
281.2 B
Quarterly Revenue Growth YOY
0.47
Return On Assets
0.13
Return On Equity
0.37
The market value of Pfizer Inc is measured differently than its book value, which is the value of Pfizer that is recorded on the company's balance sheet. Investors also form their own opinion of Pfizer's value that differs from its market value or its book value, called intrinsic value, which is Pfizer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pfizer's market value can be influenced by many factors that don't directly affect Pfizer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine Pfizer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.